ZARELIS RETARD 150 MG COMPRIMIDOS DE LIBERACION PROLONGADA Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zarelis retard 150 mg comprimidos de liberacion prolongada

italfarmaco s.a. - venlafaxina hidrocloruro - comprimido de liberaciÓn prolongada - 150 mg - venlafaxina hidrocloruro 150 mg - venlafaxina

ZARELIS RETARD 225 MG COMPRIMIDOS DE LIBERACION PROLONGADA Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zarelis retard 225 mg comprimidos de liberacion prolongada

italfarmaco s.a. - venlafaxina hidrocloruro - comprimido de liberaciÓn prolongada - 225 mg - venlafaxina hidrocloruro 225 mg - venlafaxina

ZARELIS RETARD 75 MG COMPRIMIDOS DE LIBERACION PROLONGADA Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zarelis retard 75 mg comprimidos de liberacion prolongada

italfarmaco s.a. - venlafaxina hidrocloruro - comprimido de liberaciÓn prolongada - 75 mg - venlafaxina hidrocloruro 75 mg - venlafaxina

ZARELIS RETARD 300 MG COMPRIMIDOS DE LIBERACION PROLONGADA Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zarelis retard 300 mg comprimidos de liberacion prolongada

italfarmaco s.a. - venlafaxina hidrocloruro - comprimido de liberaciÓn prolongada - 300 mg - venlafaxina hidrocloruro 300 mg - venlafaxina

Degarelix Accord Europeiska unionen - spanska - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - neoplasmas prostáticos - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Firmagon Europeiska unionen - spanska - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelix - neoplasmas prostáticos - terapia endocrina - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.